论文部分内容阅读
非霍杰金氏淋巴瘤（NHL）是恶性淋巴瘤中的一种，是常见多发性肿瘤。本病的发病人数仍在不断增多，北美每年确诊的新病例近40000例，经常规治疗失败或复发者，用大剂量药物治疗（HDT）加自体或异体造血于细胞移植是公认的治疗方法[1]。在我国，淋巴瘤的特点是NHL的发病率比霍杰
Non-Hodgkin’s lymphoma (NHL) is a type of malignant lymphoma that is a common multiple tumor. The number of people suffering from the disease is still increasing. There are nearly 40,000 new cases diagnosed in North America each year. With routine treatment failures or relapses, it is a well-recognized treatment method to use high-dose drug therapy (HDT) plus autologous or allogeneic hematopoiesis for cell transplantation [ 1]. In our country, lymphoma is characterized by a higher incidence of NHL than Huojie